08:10 AM EST, 12/11/2024 (MT Newswires) -- ImmunityBio ( IBRX ) said Wednesday it priced a public offering of 33.3 million shares at $3 per share for gross proceeds of about $100 million.

The company has given underwriters a 30-day option to purchase up to an additional 5 million shares at the offering price, minus underwriting discounts and commissions.

Proceeds from the offering, scheduled to close Thursday, are intended to fund continued commercialization of Anktiva for treating BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma in situ with or without papillary tumors, and to support trials for BCG-naive NMIBC and non-small cell lung cancer, research and development, working capital needs, and other general corporate purposes.